Multislice CT scanning with contrast enhancement can accurately detect pancreatic cancer in just one pass, according to an Italian study published in the April issue of the American Journal of Roentgenology. It can also identify candidates for surgical resection.
Multislice CT scanning with contrast enhancement can accurately detect pancreatic cancer in just one pass, according to an Italian study published in the April issue of the American Journal of Roentgenology. It can also identify candidates for surgical resection.
Dual-phase helical CT can help physicians diagnose and stage pancreatic malignancies accurately. But it is not as helpful in predicting which lesions could be surgically removed to boost survival. Patients frequently present with advanced disease at the time of diagnosis, and their chances for curative resection drop accordingly.
Dr. Massimo Imbriaco, a radiologist at the University Federico II of Naples, described in 2002 how a single-phase scan-performed in the opposite direction of standard protocols-could provide superior diagnostic accuracy compared with biphasic scanning. This technique was validated only on single-slice CT, however.
Imbriaco and colleagues have since performed single-phase MSCT scanning with contrast in 71 patients with suspected pancreatic carcinoma. They found the new protocol provided accurate diagnosis faster and less expensively than the dual-phase approach, with a lower radiation burden. They also found single-phase MSCT useful in identifying candidates for surgical resection.
A single-phase MSCT acquisition in caudocranial mode might become an alternative to standard dual-phase protocols, the investigators said.
Two experienced abdominal radiologists read the scans independently and at random. They characterized pancreatic lesions and determined their viability for resection. Tumor diagnosis using the proposed protocol provided sensitivities of 95% and 94% and specificities of 93% and 90% for the two reviewers.
The same parameters used in the assessment of tumor resection recorded sensitivities of 94% and 89% and specificities of 90% and 78%. Differences in the compared interpretative results between the two radiologists were not statistically significant.
The data acquisition protocol included caudocranial scanning from the inferior margin of the liver to the diaphragm at 4 x 1-mm slice thickness, 1.25-mm reconstruction interval, 120 kVp and 260 to 280-mAs, pitch 1, and a scanning delay of 60 seconds after contrast injection. Researchers used dedicated software/hardware for image interpretation with a volume rendering technique.
Earlier trials using dual-phase scanning had found that MSCT improved early detection and accurate staging of pancreatic cancer through greater parenchymal, arterial, and portal venous enhancement. The Italian study validates these findings but also finds advantages in single-phase over dual-phase imaging in terms of cost-effectiveness and ease of implementation.
The study had several limitations. Radiation dosage did not consider patients' physiologic differences. A 60-second scanning delay after IV injection may not be ideal for detection of hypervascular pancreatic tumors. And the sample of malignancies was too small.
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.
Emerging MRI Scoring System May Help Predict Recurrent and Metastatic Hepatocellular Carcinoma
February 12th 2025Preoperative use of the scoring system for gadoxetic acid-enhanced MRI demonstrated an average AUC of 85 percent and average specificity of 89 percent in external validation cohorts for pathologic features of hepatocellular carcinoma.
Key Chest CT Parameters for Body Composition May be Prognostic for Patients with Resectable NSCLC
February 11th 2025A high intermuscular adipose index has a 49 percent increased likelihood of being associated with lower overall survival in patients with resectable non-small cell lung cancer (NSCLC), according to new research.